CJC-1295 No DAC / Hexarelin

A two-component preparation pairing a 29-residue amidated GRF(1-29) analog with a synthetic hexapeptide.

Molecular Profile

Type
Peptide blend

Components

CJC-1295 (No DAC / Modified GRF 1-29)

Molecular formula
C152H252N44O42
Molecular weight
~3,368 g/mol
CAS number
863288-34-0
Sequence
Tetrasubstituted GRF(1-29), C-terminal amide (D-Ala at position 2)

Hexarelin

Molecular formula
C47H58N12O6
Molecular weight
887.04 g/mol
CAS number
140703-51-1
Sequence
His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2

Mechanism & Target Class

Pairs two structurally distinct synthetic peptides. CJC-1295 (No DAC) / Modified GRF 1-29 is a 29-residue, C-terminally amidated analog corresponding to residues 1-29 of a 44-residue hypothalamic peptide, carrying four substitutions relative to the parent sequence (a D-alanine at position 2 plus changes at positions 8, 15, and 27) that confer resistance to enzymatic cleavage; its structural partner is a class B GPCR, characterized by cryo-EM. Hexarelin is a synthetic hexapeptide (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) whose structural partner is a class A GPCR; photoaffinity cross-linking has additionally identified the scavenger receptor CD36 as a binding partner in cardiac-membrane preparations. The two components are structurally unrelated and engage different binding partners; no single molecular target applies to the blend.

Storage & Handling

Lyophilized
-20°C; typically stable 24-36 months desiccated and protected from light.
Handling
Avoid freeze-thaw; aliquot; protect from light and moisture.

References (20)

  1. Reviews

    1

    Ghigo E, et al. (1997). Eur J Endocrinol

    DOI: 10.1530/eje.0.1360445PubMed 9186261

  2. 2

    Bowers CY. (1998). Cell Mol Life Sci

    DOI: 10.1007/s000180050257PubMed 9893708

  3. Clinical

    3

    Teichman SL, et al. (2006). J Clin Endocrinol Metab

    DOI: 10.1210/jc.2005-1536PubMed 16352683

  4. 4

    Ionescu M, Frohman LA. (2006). J Clin Endocrinol Metab

    DOI: 10.1210/jc.2006-1702

  5. 5

    Arvat E, et al. (2001). J Clin Endocrinol Metab

    DOI: 10.1210/jcem.86.3.7314PubMed 11238504

  6. 6

    Bowers CY, et al. (1996). J Pediatr Endocrinol Metab

    PubMed 8887169

  7. 7

    Bellone J, et al. (1995). J Clin Endocrinol Metab

    PubMed 7714074

  8. 8

    Popovic V, et al. (1995). J Clin Endocrinol Metab

    PubMed 7883854

  9. 9

    Arvat E, et al. (1994). J Clin Endocrinol Metab

    PubMed 7962341

  10. 10

    Imbimbo BP, et al. (1994). Eur J Clin Pharmacol

    PubMed 7957536

  11. 11

    Ghigo E, et al. (1994). J Clin Endocrinol Metab

    DOI: 10.1210/jcem.78.3.8126144PubMed 8126144

  12. 12

    Bowers CY, et al. (1990). J Clin Endocrinol Metab

    DOI: 10.1210/jcem-70-4-975PubMed 2108187

  13. Primary research

    13

    Structural study (cryo-EM) (2020). Nature Communications

    DOI: 10.1038/s41467-020-18945-0

  14. 14

    Xu Z, et al. (2017). PubMed

    PubMed 28321024

  15. 15

    Alba M, et al. (2006). Am J Physiol Endocrinol Metab

    DOI: 10.1152/ajpendo.00201.2006

  16. 16

    Jetté L, et al. (2005). Endocrinology

    DOI: 10.1210/en.2004-1286PubMed 15817669

  17. 17

    Bodart V, et al. (2002). Circulation Research

    DOI: 10.1161/01.RES.0000016164.02525.B4

  18. 18

    Giustina A, et al. (1997). Regul Pept

    DOI: 10.1016/s0167-0115(97)00017-7PubMed 9250581

  19. 19

    Bodart V, et al. (1999). Circ Res

    DOI: 10.1161/01.res.85.9.796PubMed 10532947

  20. 20

    Bresciani E, et al. (2004). Neuroendocrinology

    DOI: 10.1159/000080793PubMed 15361691